



## **SurModics to Webcast Ophthalmic License and Research Collaboration Agreement Conference Call**

June 27, 2007

Webcast is Live at 7:30 a.m. (CT) Today

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 27, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced that it will host a live webcast of its Ophthalmic License and Research Collaboration Agreement conference call today at 7:30 a.m. CT.

Bruce Barclay, President and Chief Executive Officer, Phil Ankeny, Senior Vice President and Chief Financial Officer, and Paul Lopez, Ophthalmology Division President, will discuss the signing of a new broad-based license and research collaboration agreement between SurModics and Merck & Co., Inc. (NYSE: MRK). To access the webcast, go to the investor relations portion of the company's web site, [www.surmodics.com](http://www.surmodics.com), and click on the webcast icon.

The direct dial-in number for the conference call is 800-257-2101. An audio replay will be available beginning at 9:30 a.m. CT on Wednesday, June 27, until 9:30 p.m. CT on Wednesday, July 4, and can be accessed by dialing 800-405-2236 and entering conference call ID 11092725. In addition, the conference call audio will be archived on the company's web site following the call.

About SurModics, Inc.

SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo(TM) drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products. SurModics is headquartered in Eden Prairie, MN. More information about the company can be found at [www.surmodics.com](http://www.surmodics.com). The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.

CONTACT: SurModics, Inc.  
Phil Ankeny, (952) 829-2700  
Senior Vice President and Chief Financial Officer

SOURCE: SurModics, Inc.